SLDB
NASDAQSolid Biosciences Inc.
Price$6.61-0.18 (-2.65%)
01:30 PM07:45 PM
News · 26 weeks83-73%
2025-12-142026-06-07
Mix3290d
- Other12(38%)
- SEC Filings12(38%)
- Insider7(22%)
- Analyst1(3%)
Latest news
25 items- SECSolid Biosciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Solid Biosciences Inc. (0001707502) (Filer)
- SECSEC Form 424B7 filed by Solid Biosciences Inc.424B7 - Solid Biosciences Inc. (0001707502) (Filer)
- PRSolid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CHARLESTOWN, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 6,580 restricted stock units ("RSUs") to one newly hired employee. The RSUs vest in four equal installments on each one-year anniversary of the grant date until the fourth anniversary of the grant date. Vesting of the equity awards is subject to the applicable employee's continued service with the Company through each applicable vesting date. This grant was made pursuant to the Company's 2024 Inducement Stock Incentive Plan and was made as an inducem
- PRSolid Biosciences to Participate at Upcoming Investor ConferencesCHARLESTOWN, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences: Jefferies Global Healthcare ConferenceBo Cumbo, President and CEO, will be presenting on Wednesday, June 3, 2026, at 7:35 a.m. ET.A live webcast of the presentation will be available on the Events page of the Investors section of the Company website or by clicking here. The webcast replay will be archived for 90 days on the Events page. Goldman Sachs 47th Annual Global Healthcare ConferenceMr. Cumbo wi
- PRSolid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates- Duchenne (SGT-003): First participant dosed in the Phase 3 IMPACT DUCHENNE clinical trial, receipt of positive opinion on the Company's Pediatric Investigation Plan from the European Medicines Agency and Orphan drug designation from the European Commission mark important advancements in the program's global development - - Continued progress achieved across the SGT-003 development program, including dosing of 47 participants in Phase 1/2 INSPIRE DUCHENNE clinical trial, and ongoing engagement with the FDA for guidance on a potential accelerated approval pathway for SGT-003 - - Friedreich's Ataxia (SGT-212): Second participant dosed in the Phase 1b FALCON clinical trial; SGT-212 has been
- SECSEC Form 10-Q filed by Solid Biosciences Inc.10-Q - Solid Biosciences Inc. (0001707502) (Filer)
- PRSolid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular Dystrophy- Initiation of Phase 3 IMPACT DUCHENNE placebo-controlled, randomized, double-blind trial as part of Solid's integrated, multi-trial development program designed to support registration and global regulatory authorizations for SGT-003 - - Solid received a positive opinion from the European Medicines Agency (EMA) on its Pediatric Investigation Plan (PIP) for SGT-003, establishing alignment on a pediatric clinical development framework in Europe - - 46 participants have been dosed with SGT-003 in the Phase 1/2 INSPIRE DUCHENNE clinical trial using a steroid-only prophylactic immunomodulation regimen; SGT-003 has been generally well tolerated as of a May 4, 2026, cutoff date - CHARLESTOWN,
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Solid Biosciences Inc.SCHEDULE 13G/A - Solid Biosciences Inc. (0001707502) (Subject)
- PRSolid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CHARLESTOWN, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 8,070 restricted stock units ("RSUs") to one newly hired employee. The RSUs vest in four equal installments on each one-year anniversary of the grant date until the fourth anniversary of the grant date. Vesting of the equity awards is subject to the applicable employee's continued service with the Company through each applicable vesting date. This grant was made pursuant to the Company's 2024 Inducement Stock Incentive Plan and was made as an inducement m
- PRSolid Biosciences to Showcase a Large Presence at the 29th Annual Meeting of the American Society of Gene and Cell Therapy- Solid Biosciences delivers its largest scientific program at the 2026 ASGCT Annual Meeting with 5 oral presentations and 11 posters - CHARLESTOWN, Mass., April 30, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that multiple abstracts have been accepted for presentation at the upcoming 29th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), taking place May 11-15, 2026, in Boston, MA. Solid Biosciences will deliver its largest number of presentations for the Company, reflecting the growing breadth and dept
- PRSolid Biosciences Announces Receipt of European Commission Orphan Drug Designation for SGT-003 for the Treatment of Duchenne Muscular Dystrophy- Orphan drug designation from the European Commission underscores Solid's commitment to advance SGT-003 through a global development effort for individuals living with Duchenne muscular dystrophy - CHARLESTOWN, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that the European Commission (EC), acting upon the positive opinion from the European Medicines Agency Committee for Orphan Medicinal Products, has granted Orphan drug designation to SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne). "This
- SECSEC Form DEFA14A filed by Solid Biosciences Inc.DEFA14A - Solid Biosciences Inc. (0001707502) (Filer)
- SECSEC Form DEF 14A filed by Solid Biosciences Inc.DEF 14A - Solid Biosciences Inc. (0001707502) (Filer)
- INSIDERSEC Form 4 filed by Tan Kevin4 - Solid Biosciences Inc. (0001707502) (Issuer)
- INSIDERSEC Form 4 filed by Herzich Paul4 - Solid Biosciences Inc. (0001707502) (Issuer)
- INSIDERSEC Form 4 filed by Brooks Gabriel4 - Solid Biosciences Inc. (0001707502) (Issuer)
- INSIDERSEC Form 4 filed by Cumbo Alexander4 - Solid Biosciences Inc. (0001707502) (Issuer)
- INSIDERSEC Form 4 filed by Howton David T4 - Solid Biosciences Inc. (0001707502) (Issuer)
- INSIDERSEC Form 4 filed by Hanrahan Jessie4 - Solid Biosciences Inc. (0001707502) (Issuer)
- SECSEC Form PRE 14A filed by Solid Biosciences Inc.PRE 14A - Solid Biosciences Inc. (0001707502) (Filer)
- SECSolid Biosciences Inc. filed SEC Form 8-K: Leadership Update8-K - Solid Biosciences Inc. (0001707502) (Filer)
- PRSolid Biosciences to Participate at Upcoming Investor ConferencesCHARLESTOWN, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the "Company" or "Solid"), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences: 25th Annual Needham Virtual Healthcare ConferenceBo Cumbo, President and CEO, will participate in a virtual fireside chat on Tuesday, April 14, 2026, at 2:15 pm ET.A live webcast of the presentation will be available on the Events page of the Investors section of the Company website or by clicking here. The webcast replay will be archived for 90 days on the Events page. Piper Sandler Spring Biopharma
- INSIDERSEC Form 4 filed by Smith Ian F4 - Solid Biosciences Inc. (0001707502) (Issuer)
- SECSEC Form EFFECT filed by Solid Biosciences Inc.EFFECT - Solid Biosciences Inc. (0001707502) (Filer)
- SECSEC Form EFFECT filed by Solid Biosciences Inc.EFFECT - Solid Biosciences Inc. (0001707502) (Filer)
SLDB FAQ
7 questionsWhat does Solid Biosciences Inc. do?
Solid Biosciences Inc., a life science company, engages in developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles. Its portfolio also comprises Anti-LTBP4, a complementary disease modifying program that identifies and develops a monoclonal antibody intended to reduce fibrosis and inflammation by targeting and stabilizing the LTBP4 protein. In addition, the company engages in...Where does SLDB stock trade?
Solid Biosciences Inc. (SLDB) is listed on NASDAQ.What sector and industry is SLDB in?
Solid Biosciences Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Solid Biosciences Inc. go public?
Solid Biosciences Inc. (SLDB) completed its IPO in 2018.What are analysts saying about SLDB?
Solid Biosciences Inc. has had 8 recent analyst actions on file. The most recent action was from Guggenheim: Buy with a $2600.00 price target on 2026-03-20. Recent price targets range from $1200.00 to $2600.00.What companies are similar to SLDB?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare SLDB side-by-side with any of them on Quantisnow.How can I track SLDB on Quantisnow?
Quantisnow aggregates Solid Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SLDB to receive live email and push alerts on every new disclosure.